Skip to main content
IMMUNIC, INC. logo

IMMUNIC, INC. — Investor Relations & Filings

Ticker · IMUX ISIN · US4525EP1011 LEI · 549300R5T12FW5MEQB20 US Professional, scientific and technical activities
Open in API
Filings indexed 786 across all filing types
Latest filing 2026-03-03 Regulatory Filings
Country US United States of America
Listing US IMUX

About IMMUNIC, INC.

https://imux.com/

Immunic, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of selective, orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's mission is to create high-quality, oral treatment options that offer comprehensive therapeutic efficacy with favorable safety and tolerability profiles. Its clinical development programs target conditions with significant unmet medical needs, including multiple sclerosis and celiac disease, aiming to provide patients with convenient and effective solutions to manage debilitating symptoms and improve their quality of life.

Recent filings

Filing Released Lang Actions
Immunic to Participate in Investor Conferences in March
Regulatory Filings Classification · 1% confidence The document is a press release announcing the company's participation in upcoming investor conferences. It does not contain financial results, audit reports, or governance disclosures, but rather serves as a general corporate announcement regarding investor relations activities. As it does not fit into specific categories like earnings releases or reports, it is classified as a general regulatory/corporate announcement.
2026-03-03 English
DEF 14A - IMMUNIC, INC. (0001280776) (Filer)
Proxy Solicitation & Information Statement
2026-03-02 English
10-K - IMMUNIC, INC. (0001280776) (Filer)
Annual Report FY 2025
2026-02-26 English
8-K - IMMUNIC, INC. (0001280776) (Filer)
Regulatory Filings
2026-02-26 English
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
Earnings Release Classification · 1% confidence The document is a press release titled 'Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update'. It provides a summary of financial highlights, R&D expenses, net loss, and cash position for the fiscal year ended December 31, 2025. While it contains financial data, it is structured as a corporate announcement (press release) rather than a formal 10-K filing. According to the 'Menu vs Meal' rule, this is an initial announcement of results, which falls under the Earnings Release (ER) category. FY 2025
2026-02-26 English
Immunic Announces Closing of Oversubscribed Private Placement Financing
Capital/Financing Update Classification · 1% confidence The document is a corporate press release announcing the closing of a private placement financing transaction. It details the issuance of warrants and the intended use of proceeds. This falls under the category of capital and financing updates, as it describes a specific fundraising activity rather than a general regulatory filing or a periodic report.
2026-02-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.